Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Rashmi Kanagal-Shamanna, Haiyan Bao, Hutton Kearney, Stephanie Smoley, Zhenya Tang, Rajyalakshmi Luthra, Hui Yang, Shanshan Zhang, Pei Lin, Depei Wu, L. Jeffrey Medeiros & Xinyan Lu. (2022) Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia. Leukemia & Lymphoma 63:4, pages 865-875.
Read now
Read now
Mónica Villa-Álvarez, Seila Lorenzo-Herrero, Ana P. Gonzalez-Rodriguez, Alejandro López-Soto, Angel R. Payer, Esther Gonzalez-Garcia, Leticia Huergo-Zapico & Segundo Gonzalez. (2017) Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia. OncoImmunology 6:10.
Read now
Read now
Carol Lozano-Santos, José A. García-Vela, Nuria Pérez-Sanz, Sara Nova-Gurumeta, Belen Fernandez-Cuevas, Natalia Gomez-Lozano, Margarita Sánchez-Beato, Pedro Sanchez-Godoy, José Luis Bueno & José A. Garcia-Marco. (2017) Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion. Leukemia & Lymphoma 58:4, pages 859-865.
Read now
Read now
Jan Verner, Martin Trbusek, Jana Chovancova, Zuzana Jaskova, Mojmir Moulis, Frantisek Folber, Roman Halouzka, Jiri Mayer, Sarka Pospisilova & Michael Doubek. (2015) NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines. Leukemia & Lymphoma 56:11, pages 3198-3206.
Read now
Read now
Johannes Winkler, Kay Hofmann & Shuhua Chen. (2014) Novel targets for ATM-deficient malignancies. Molecular & Cellular Oncology 1:1.
Read now
Read now
Articles from other publishers (45)
Ti’ara L. Griffen, Fieke W. Hoff, Yihua Qiu, Jan Burger, William Wierda & Steven M. Kornblau. (2023) Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences 24:6, pages 5481.
Crossref
Crossref
Sara E. F. Kost, Ali Saleh, Shek H. Yuan, Bozena Kuzio, Spencer B. Gibson, Lin Yang, Versha Banerji, James B. Johnston & Sachin Katyal. (2023) DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease. Blood Cancer Journal 13:1.
Crossref
Crossref
Jakub Czarny, Marta Andrzejewska, Olga Zając-Spychała, Elżbieta Latos-Grażyńska, Agata Pastorczak, Kamila Wypyszczak, Aleksandra Szczawińska-Popłonyk, Izabela Niewiadomska-Wojnałowicz, Agnieszka Wziątek, Patrycja Marciniak-Stępak, Michał Dopierała, Jadwiga Małdyk, Katarzyna Jończyk-Potoczna & Katarzyna Derwich. (2023) Successful Treatment of Large B-Cell Lymphoma in a Child with Compound Heterozygous Mutation in the ATM Gene. International Journal of Molecular Sciences 24:2, pages 1099.
Crossref
Crossref
Ming Yin, Feng Hong & Qi-En Wang. 2022. Metastasis. Metastasis
117
136
.
Marina Lafage-PochitaloffBastien Gerby, Véronique Baccini, Laetitia Largeaud, Vincent Fregona, Naïs Prade, Pierre-Yves JuvinLaura Jamrog, Pierre BoriesSylvie HébrardStéphanie LagardeVéronique Mansat-De Mas, Oliver M. Dovey, Kosuke Yusa, George S. Vassiliou, Joop H. Jansen, Tobias Tekath, David Rombaut, Geneviève Ameye, Carole BarinAudrey BidetJohn BoudjaraneMarie-Agnès Collonge-RameCarine GervaisAntoine Ittel, Christine LefebvreIsabelle LuquetLucienne Michaux, Nathalie NadalHélène A. Poirel, Isabelle Radford-WeissBénédicte RibourtoutSteven RichebourgStéphanie Struski, Christine TerréIsabelle TigaudDominique PentherVirginie Eclache, Michaela Fontenay, Cyril Broccardo & Eric Delabesse,. (2022)
The
CADM1
tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
. Blood Advances 6:2, pages 386-398.
Crossref
Crossref
Yi-Xin Zou, Han-Ning Tang, Jing Zhang, Xiao-Lu Tang, Shu-Chao Qin, Yi Xia, Hua-Yuan Zhu, Chun Qiao, Li Wang, Lei Fan, Wei Xu, Jian-Yong Li & Yi Miao. (2021) Low prevalence and independent prognostic role of del(11q) in Chinese patients with chronic lymphocytic leukemia. Translational Oncology 14:10, pages 101176.
Crossref
Crossref
Beata Balla, Florin Tripon & Claudia Banescu. (2021) From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques. International Journal of Molecular Sciences 22:18, pages 10065.
Crossref
Crossref
Viktor Ljungström & Panagiotis Baliakas. (2021) Prognostic and Predictive Implications of Cytogenetics and Genomics. Hematology/Oncology Clinics of North America 35:4, pages 703-713.
Crossref
Crossref
Miguel Quijada-Álamo, María Hernández-Sánchez, Ana-Eugenia Rodríguez-Vicente, Claudia Pérez-Carretero, Alberto Rodríguez-Sánchez, Marta Martín-Izquierdo, Verónica Alonso-Pérez, Ignacio García-Tuñón, José María Bastida, María Jesús Vidal-Manceñido, Josefina Galende, Carlos Aguilar, José Antonio Queizán, Isabel González-Gascón y Marín, José-Ángel Hernández-Rivas, Rocío Benito, José Luis Ordóñez & Jesús-María Hernández-Rivas. (2021) Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression. Blood Cancer Journal 11:7.
Crossref
Crossref
Annapaola Angrisani, Annamaria Di Fiore, Enrico De Smaele & Marta Moretti. (2021) The emerging role of the KCTD proteins in cancer. Cell Communication and Signaling 19:1.
Crossref
Crossref
Vincenza Ylenia Cusenza, Alessandra Bisagni, Monia Rinaldini, Chiara Cattani & Raffaele Frazzi. (2021) Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches. International Journal of Molecular Sciences 22:9, pages 4732.
Crossref
Crossref
Anya K. Hotinski, Oliver G. Best & Bryone J. Kuss. (2021) The future of laboratory testing in chronic lymphocytic leukaemia. Pathology 53:3, pages 377-384.
Crossref
Crossref
Miguel Quijada‐Álamo, Claudia Pérez‐Carretero, María Hernández‐Sánchez, Ana‐Eugenia Rodríguez‐Vicente, Ana‐Belén Herrero, Jesús‐María Hernández‐Sánchez, Marta Martín‐Izquierdo, Sandra Santos‐Mínguez, Mónica del Rey, Teresa González, Araceli Rubio‐Martínez, Alfonso García de Coca, Julio Dávila‐Valls, José‐Ángel Hernández‐Rivas, Helen Parker, Jonathan C. Strefford, Rocío Benito, José‐Luis Ordóñez & Jesús‐María Hernández‐Rivas. (2021)
Dissecting the role of
TP53
alterations in del(11q) chronic lymphocytic leukemia
. Clinical and Translational Medicine 11:2.
Crossref
Crossref
Ming Yin, Petros Grivas, Qi-En Wang, Amir Mortazavi, Hamid Emamekhoo, Sheldon L. Holder, Joseph J. Drabick, Michele Sue-Ann Woo, Sumanta Pal, Monali Vasekar, Edmund Folefac, Steven K. Clinton, Paul Monk & Monika Joshi. (2020) Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer. The Oncologist 25:8, pages 680-688.
Crossref
Crossref
Yueting Li, Pengxu Shi & Daqing Jiang. (2020)
Polymorphism rs1801516 (G > A) in the
ATM
gene is not associated with overall cancer risk: an updated meta-analysis
. Journal of International Medical Research 48:7, pages 030006052093761.
Crossref
Crossref
Rebecca L. Lloyd, Paul W. G. Wijnhoven, Antonio Ramos-Montoya, Zena Wilson, Giuditta Illuzzi, Katarzyna Falenta, Gemma N. Jones, Neil James, Christophe D. Chabbert, Jonathan Stott, Emma Dean, Alan Lau & Lucy A. Young. (2020) Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene 39:25, pages 4869-4883.
Crossref
Crossref
Miguel Quijada-Álamo, María Hernández-Sánchez, Verónica Alonso-Pérez, Ana E. Rodríguez-Vicente, Ignacio García-Tuñón, Marta Martín-Izquierdo, Jesús María Hernández-Sánchez, Ana B. Herrero, José María Bastida, Laura San Segundo, Michaela Gruber, Juan Luis García, Shanye Yin, Elisa ten Hacken, Rocío Benito, José Luis Ordóñez, Catherine J. Wu & Jesús María Hernández-Rivas. (2020) CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia 34:6, pages 1599-1612.
Crossref
Crossref
Kartik Viswanathan, Gail Roboz, Amy Chadburn & Susan Mathew. (2019) Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. International Journal of Surgical Pathology 28:2, pages 216-224.
Crossref
Crossref
Ferran NadeuAnder Diaz-Navarro, Julio Delgado, Xose S. Puente & Elías Campo. (2020) Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia. Annual Review of Pathology: Mechanisms of Disease 15:1, pages 149-177.
Crossref
Crossref
Zhi-liang Zhao, Lu Xia, Cong Zhao & Jun Yao. (2019) ATM rs189037 (G > A) polymorphism increased the risk of cancer: an updated meta-analysis. BMC Medical Genetics 20:1.
Crossref
Crossref
Boyu Hu, Keyur P. Patel, Hsiang‐Chun Chen, Xuemei Wang, Rajyalakshmi Luthra, Mark J. Routbort, Rashmi Kanagal‐Shamanna, L. Jeffrey Medeiros, C. Cameron Yin, Zhuang Zuo, Chi Y. Ok, Sanam Loghavi, Guilin Tang, Francesco P. Tambaro, Philip Thompson, Jan Burger, Nitin Jain, Alessandra Ferrajoli, Prithviraj Bose, Zeev Estrov, Michael Keating & William G. Wierda. (2019) Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patients. British Journal of Haematology 187:3, pages 307-318.
Crossref
Crossref
Francesc Bosch & Riccardo Dalla-Favera. (2019) Chronic lymphocytic leukaemia: from genetics to treatment. Nature Reviews Clinical Oncology 16:11, pages 684-701.
Crossref
Crossref
Weng, Lin & Cheng. (2019) The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer. Journal of Clinical Medicine 8:9, pages 1369.
Crossref
Crossref
Judith Schütte, Julia Reusch, Cyrus Khandanpour & Christine Eisfeld. (2019) Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies. Frontiers in Oncology 9.
Crossref
Crossref
María Hernández-Sánchez, Ana Eugenia Rodríguez-Vicente, Isabel González-Gascón y Marín, Miguel Quijada-Álamo, Jesús María Hernández-Sánchez, Marta Martín-Izquierdo, José Ángel Hernández-Rivas, Rocío Benito & Jesús María Hernández-Rivas. (2019) DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains. Experimental Hematology 72, pages 9-13.
Crossref
Crossref
Ali Sakhdari, Guilin Tang, Lawrence E. Ginsberg, Cheryl F. Hirsch-Ginsberg, Carlos E. Bueso-Ramos, L. Jeffrey Medeiros & Roberto N. Miranda. (2019) Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy. Case Reports in Pathology 2019, pages 1-10.
Crossref
Crossref
Meijun Du, Jonathan Thompson, Hannah Fisher, Peng Zhang, Chiang-Ching Huang & Liang Wang. (2018) Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance. Lung Cancer 120, pages 113-121.
Crossref
Crossref
David Corujo & Marcus Buschbeck. (2018) Post-Translational Modifications of H2A Histone Variants and Their Role in Cancer. Cancers 10:3, pages 59.
Crossref
Crossref
V. Bakthavatchalu & S. Muthupalani. 2018. Comprehensive Toxicology. Comprehensive Toxicology
363
395
.
Nicholas J. Davies, Marwan Kwok, Clive Gould, Ceri E. Oldreive, Jingwen Mao, Helen Parry, Edward Smith, Angelo Agathanggelou, Guy Pratt, Alexander Malcolm R. Taylor, Paul Moss, Mike Griffiths & Tatjana Stankovic. (2017) Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts. Oncotarget 8:27, pages 44749-44760.
Crossref
Crossref
Jennifer Goy, Tanya L. Gillan, Helene Bruyere, Steven J.T. Huang, Monica Hrynchak, Aly Karsan, Khaled Ramadan, Joseph Connors, Cynthia L. Toze & Alina S. Gerrie. (2017) Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada. Clinical Lymphoma Myeloma and Leukemia 17:6, pages 382-389.
Crossref
Crossref
Barry D. Hock, Sean A. MacPherson & Judith L. McKenzie. (2017) Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells. PLOS ONE 12:3, pages e0172858.
Crossref
Crossref
Massoud Marcel. (2017) Chronic Lymphocytic Leukemia (CLL): Upfront Treatment Options in 2017. Hematology & Transfusion International Journal 4:2.
Crossref
Crossref
Sotirios G. Papageorgiou, Christos K. Kontos, Marios A. Diamantopoulos, Anthi Bouchla, Eirini Glezou, Efthymia Bazani, Vasiliki Pappa & Andreas Scorilas. (2017) MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis. Disease Markers 2017, pages 1-10.
Crossref
Crossref
Helen ParkerJonathan C. Strefford. (2016) The mutational signature of chronic lymphocytic leukemia. Biochemical Journal 473:21, pages 3725-3740.
Crossref
Crossref
Y Jiang, H-C Chen, X Su, P A Thompson, X Liu, K-A Do, W Wierda, M J Keating & W Plunkett. (2016) ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2). Blood Cancer Journal 6:9, pages e465-e465.
Crossref
Crossref
Andrea Tomasella, Raffaella Picco, Sonia Ciotti, Andrea Sgorbissa, Elisa Bianchi, Rossella Manfredini, Fabio Benedetti, Valentina Trimarco, Federica Frezzato, Livio Trentin, Gianpietro Semenzato, Domenico Delia & Claudio Brancolini. (2016) The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells. Oncotarget 7:29, pages 45429-45443.
Crossref
Crossref
Katrien Van Roosbroeck & George A. Calin. (2016) MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?. Seminars in Oncology 43:2, pages 209-214.
Crossref
Crossref
Giulia Fabbri & Riccardo Dalla-Favera. (2016) The molecular pathogenesis of chronic lymphocytic leukaemia. Nature Reviews Cancer 16:3, pages 145-162.
Crossref
Crossref
Gera D. te Raa & Arnon P. Kater. (2016) TP53 dysfunction in CLL: Implications for prognosis and treatment. Best Practice & Research Clinical Haematology 29:1, pages 90-99.
Crossref
Crossref
Marwan KwokNicholas DaviesAngelo AgathanggelouEdward SmithCeri OldreiveEva PetermannGrant StewartJeff BrownAlan LauGuy Pratt, Helen ParryMalcolm TaylorPaul MossPeter Hillmen & Tatjana Stankovic. (2016) ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood 127:5, pages 582-595.
Crossref
Crossref
Lesley-Ann Sutton & Richard Rosenquist. (2015) The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Seminars in Cancer Biology 34, pages 22-35.
Crossref
Crossref
G D te Raa, P D Moerland, A C Leeksma, I A Derks, H Yigittop, N Laddach, M Loden-van Straaten, V Navrkalova, M Trbusek, D M Luijks, T Zenz, A Skowronska, M Hoogendoorn, T Stankovic, M H van Oers, E Eldering & A P Kater. (2015) Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification. Cell Death & Disease 6:8, pages e1852-e1852.
Crossref
Crossref
Júlia L.F. Abrantes, Thaís F. Tornatore, Karin J. Pelizzaro-Rocha, Marcelo B. de Jesus, Rodrigo T. Cartaxo, Renato Milani & Carmen V. Ferreira-Halder. (2014) Crosstalk between kinases, phosphatases and miRNAs in cancer. Biochimie 107, pages 167-187.
Crossref
Crossref
Jitka Malcikova, Sarka Pavlova, Katerina Stano Kozubik & Sarka Pospisilova. (2014) TP53 Mutation Analysis in Clinical Practice: Lessons From Chronic Lymphocytic Leukemia. Human Mutation 35:6, pages 663-671.
Crossref
Crossref